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peripheral neuropathy (17.94 vs. 11.66, p=0.088) and lymphedema 
scores was observed (10 vs. 1.66, p=0.06).  
Twenty three patients who completed 6 months since IMRT, 
demonstrated improvement in physical and emotional function and 
significant decrease in symptom scales (p< 0.05) except insomnia 
score (p=0.276). On evaluation of cervix specific module, no 
difference was observed in functional scores as compared to baseline. 
However,an improvement in body image perception (81.31 vs. 97.47, 
p=0.009) and significant decrease in peripheral neuropathy (p= 0.014) 
was observed. Though reduction in global QoL was observed, but 
scores remained higher than baseline scores.(70.28 vs. 65.21 ).  
Conclusions: Patients with cervical cancer have higher QOL scores at 
6 months after completing adjuvant IMRT than at baseline. However 
this effect needs to be confirmed at further follow up and a larger 
cohort of patients undergoing IMRT.  
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Purpose/Objective: Survivors of Hodgkin’s Lymphoma (HL) are at risk 
of secondary tumors. None of the studies of secondary cancers in HL 
survivors have focused on the risk of developing skin cancers. We 
investigated the risk of developing secondary skin cancers after 
radiation therapy for HL, both in comparison to treatment without 
radiotherapy and to an age-matched Dutch population. 
Materials and Methods: We conducted a retrospective cohort study of 
889 HL patients treated between 1965 and 2005. Data on diagnosis of 
secondary skin cancers were collected by linkage with the nationwide 
pathology database. Data on treatment fields were extracted from 
patient files. Incidence rates of skin cancers and of basal cell 
carcinoma (BCC) specifically were compared to the expected number 
based on age, sex- and calendar period-specific incidence rates in the 
Dutch population. 
Results: 318 skin cancers were diagnosed in 86 patients. The majority 
of skin cancers (93%) were BCC. The standardized incidence ratio (SIR) 
of BCC in HL survivors was significantly increased compared to the 
general population (SIR 5.2, 95% CI 4.0-6.6), especially in the group 
aged <35 years at diagnosis (SIR 8.0, 95% CI 5.8-10.7). SIR increased 
with longer follow-up; after 35 years the SIR was 15.9 (95% CI 9.1-
25.9), with 626 excess cases per 10.000 patients per year. The risk of 
skin cancer was significantly increased in patients treated with 
radiotherapy (as part of) their treatment in comparison to patients 
treated with chemotherapy alone (HR 2.75, 95% CI 1.01-7.45, 
p=0.047). 
The majority of skin cancers developed within the radiation treatment 
fields (57%). Of the skin cancers that developed outside radiotherapy 
field 15% were located in near proximity of the radiation field 
borders. 
Conclusions: Radiotherapy for HL is associated with a strongly 
increased long-term risk of developing skin cancer, both in comparison 
to the general Dutch population and to treatment with chemotherapy 
alone. Since risks increase with longer follow-up, the total number of 
skin cancers in HL survivors is expected to further increase, 
implicating a substantial and clinically relevant problem. Patients and 
health care providers should be aware of this risk, in order to 
facilitate preventive measured and rapid access to early diagnosis and 
treatment. 
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Purpose/Objective: The standard treatment today is maximal surgical 
resection followed by concomitant chemo-radiation therapy followed 
by adjuvant TMZ , with median overall survival of 14.6 months and 2-
year survival rate of 26.5%. Despite the progress in neurosurgery, 
radiotherapy and oncology, the prognosis still result poor. In order to 
reduce the long time of standard treatment, in our institute we 
investigated the effects of hypofractionated radiation therapy (HFRT). 
For comparison, a group of 25 patients with similar characteristics and 
treated with Stupp protocol was retrospectively selected.  
Materials and Methods: 67 patients affected by GBL underwent 
surgical resection were treated between October 2005 and December 
2011 with HFRT followed or not by adjuvant chemotherapy with 
temozolomide (6-12 cycles). HFRT (5 Gy/fraction/day) was delivered 
to a total dose of 25 Gy in 5 fractions, dose prescribed at the 70% 
isodose. All patients received a non-contrast CT scan and MRI for 
treatment planning. After image fusion, the target volume was 
defined by the contrast-enhanced tumour edges on axial T1 and FLAIR 
sequences by consensus agreement of the neurosurgeon, 
neuroradiologist, and radiation oncologist. Treatment planning was 
performed to cover the 100% of planning target volume by 25 Gy, with 
maximum dose of 35.7 Gy. For treatment delivery, all patients 
received an portal image prior to each treatment fraction. Sex, age, 
type of surgery, Karnofsky performance status, Recursive Partitioning 
Analysis (RPA) classification, time between surgery and initiation of 
radiotherapy were analyzed as potential prognostic factors for survival 
using the univariate log-rank method.  
Results: All patients have completed the treatment protocol. Median 
age was 64,5 years (range 41-82 yrs) with 31 females (46%) and 36 
males (54%). Median KPS at time of treatment was 80. The surgery 
was gross total in 38 patients and subtotal in 14 patients; 15 patients 
underwent only biopsy. The patients characteristics of the two groups 
of patients are similar. With mean follow-up of 14.9 months (range 3-
62 months), the median overall survival and median progression- free 
survival were 12.43 and 6.9 months, respectively. No grade 3-4 acute 
or late neurotoxicity was observed. Post-treatment median KPS was 90 
(range 70-100). The overall tolerance of patients to HFRT was not 
different from that for conventional radiotherapy. Not statistically 
significant difference in terms of overall survival between HFRT group 
and Stupp protocol group was reported (p 0.12). 
Conclusions: The HFRT can be used for patients with GBL , resulting 
in favourable overall survival, low rates of toxicity and satisfying QoL. 
Future investigations are needed to determine the optimal 
fractionation for GBL. 
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Purpose/Objective: There is no established therapy for meningiomas 
that recur after surgery and radiotherapy. We carried out a pilot study 
to establish the tolerability and therapeutic potential of 177Lu-
DOTATATE(DOTA) which targets somatostatin receptors (sstr). 
Materials and Methods: 6 patients with recurrent progressive G2 
meningioma underwent 68Ga-DOTA PET/CT to assess eligibility for 
treatment (tx). 4 cycles of 7.4GBq 177Lu-DOTA were planned at 8-10 
week intervals.  
Protocol: antiemetic, cationic amino acid infusion to prevent renal 
toxicity (25g lysine/25g arginine in 1L of 0.9%NaCl over 4 hr), iv 
injection of 177Lu-DOTA (30 mins), short course of dexamethasone to 
prevent neuroaxial oedema, weekly full blood count monitoring for 6 
weeks. 
Metabolic activity was assessed on 68Ga-DOTA PET/CT prior to tx and 
at 1 year. Tumour size was evaluated on MRI by RECIST(1D) and WHO 
(2D) criteria and on a volumetric basis to establish a growth rate(GR) 
pre and post tx: GR= log10 (Vt/V0)/dt (exponential) and % growth per 
month (linear). 
Dosimetry was performed on cycle 2 for 1 patient. Post-tx whole body 
imaging and SPECT/CT was performed at 2.2,4.8, 21.4 and 92.6 hrs. 
Tumour volume was defined with contrast-enhanced CT at 21.4 hrs. 
Using a phantom derived SPECT sensitivity factor, the activity in the 
tumour at each time point was determined and a biexponential fitted 
to the time-activity curve. Accumulated activity was multiplied by the 
relevant s-factor determined for a spherical mass calculated from the 
tumour volume.  
Results: All 6 patients had sstr +ve disease and commenced tx. 4 
patients completed 4 cycles with minimal toxicity(G1 fatigue and G1 
thrombocytopenia in 1 patient). Median administered dose was 
7.4GBq, median interval 10 weeks. An overnight stay was required for 
radiation protection. 2 patients demonstrated symptom improvement 
(reduced seizures,improved muscle power). 2 patients stopped after 1 
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cycle due to continued deterioration in performance status (both 
ECOG PS 3 pre-tx).  
All patients had PD on pre-tx imaging.Table 1 summarises results.  
 
All tumours increased in size although tumour growth rates at 1 year 
were substantially lower than pre-tx in 3 patients(p=0.28, small 
patient numbers). There was no clear trend in SUVmax. Volumetric 
growth rate analysis appeared to most accurately reflect growth in 
meningiomas which often grow irregularly. 
Dosimetric analysis found that 7.4GBq administered dose equated to 
43Gy in the tumour, but a further scan at 35 hrs would have been 
helpful. Regions of 177Lu-DOTA therapy uptake mirrored regions of 
tracer avidity on 68Ga-DOTA scans.  
Conclusions: 177Lu-DOTA is well tolerated and may reduce growth 
rates in some patients with advanced meningioma. Larger studies in 
patients of good PS are required. As 177Lu emits γ rays, dosimetric 
evaluation of tumour uptake is possible and prescribed dose could be 
individually tailored to deliver a desired absorbed dose, however, 
further work is required to assess reliability of dose estimation.  
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Purpose/Objective: As paediatric medulloblastoma (MB) is a relatively 
rare disease, it is important to extract the most information possible 
on its response to therapy from trials and cohort studies. Here, a 
framework is developed for modeling tumor control with multiple 
modes of failure and time-to-progression, using pattern of failure data 
from published standard-risk MB series. 
Materials and Methods: Using a meta-analysis approach, data from 
reports on outcome after radio-chemotherapy in standard-risk MB 
published after 1990 and containing information on pattern of relapse 
were selected. Out of 287 screened records, 12 were included to 
derive a tumor control dose-response model addressing failures in the 
high-dose boost volume and the elective craniospinal volume. Failures 
in the boost and elective volume were assumed to be statistically 
independent and failures diagnosed as simultaneous were assumed to 
have originated in the primary site and subsequently spread to the 
elective volume. Here, we used a mixture model to describe the 
freedom from progression (FFP). The time-to-progression distribution 
was based on Kaplan-Meier estimates of 5-year event-free survival 
from two large randomized MB trials (SIOP-PNET-4 from 2012 and 
Packer et al. from 2006). The uncertainty in the estimated 5-year FFP 
was estimated by Monte Carlo sampling (2000 samples) over the 
statistical uncertainty in the input data of the dose-response model. 
Results: The estimated values of 5-year FFP, and 95% confidence 
intervals (CIs) were 69% (56-81%), 77% (74-81%), 79% (77-82%) and 82% 
(78-84%) for CSI doses of zero, 18, 24 and 36 Gy respectively, while 
keeping the boost dose constant at 54 Gy. The uncertainty in FFP 
estimates were considerably larger for craniospinal doses below 18 Gy 
compared to between 24 and 36 Gy, reflecting the limited amount of 
data in the lower dose range. 
 
Figure 1. Estimated FFP for three scenarios, zero Gy craniospinal 
irradiation (CSI), 24 Gy CSI or 36 Gy CSI. Vertical bars represent the 
95% CIs for FFP at 5 years after diagnosis (displaced slightly in the 
graph for visualization), based on 2000 Monte Carlo samples. 
 
Conclusions: We show that while keeping the boost dose constant, 
varying the CSI dose only slightly alters the estimated outcome. 
Omitting the CSI however, shows a clear drop in the estimated FFP. 
Using this model, a post-hoc power calculation for the two treatment 
regimens compared in the recently published SIOP-PNET-4 trial yields 
a statistical power, given the trial sample size, at only 13%, which 
could explain the negative result of that trial. As illustrated in Figure 
1, there are large gaps in the knowledge of the efficacy of very low 
CSI doses; therefore the tumor control estimates at low doses should 
be interpreted with caution.  
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Purpose/Objective: To evaluate the efficacy and outcome of using a 
combination of 4 - 6 cycles of Doxorubicin, Bleomycin, Vinblastine, 
and Dacarbazine (ABVD) chemotherapy (CTh) and involved field 
radiation therapy (IFRT) in the management of paediatric early stage 
unfavorable Hodgkin's lymphoma (HL). 
Materials and Methods: Seventy children less than 18yrs of age with 
early stage unfavourable HL treated with 4-6 cycles of ABVD followed 
by IFRT were included in this analysis. There were 59 (84.3%) males 
and 11 (15.7%) females. The commonest histological subtype was 
mixed cellularity. Majority of the patients (54%) had stage IIAX 
disease. Based on response to CTh the radiation doses were 19.8Gy/ 
11 fractions and 30.6Gy/ 17 fractions for patients with complete 
response (CR) and partial response (PR) respectively. 
Results: After a median follow-up of 60 months, the 10 year disease 
free survival (DFS) and overall survival (OS) were 94% and 97% 
respectively. On univariate analysis prognostic factors found to have 
significant impact on DFS were, bulky disease (p=0.003), nodular 
lymphocyte predominant histology (p=0.003) and stage of disease 
(p=0.045).None of the prognostic factors had a significant impact on 
OS. On multivariate analysis using Cox regression model, none of the 
prognostic factors were found to have a significant impact on DFS and 
OS.There was no difference between 4 and 6 cycles of ABVD in terms 
of acute pulmonary, haematological and other treatment related 
acute toxicities. Grade II dermatitis for pts. receiving RTh doses more 
than 25Gy or less were 20% and 14.6% respectively, while the 
corresponding incidence of mucositis was 13.3% and 3.5% respectively. 
Conclusions: Our study supports the current standard of care for 
paediatric early stage unfavourable HL of using four cycles of ABVD 
CTh followed by IFRT. This combination results in optimal outcomes in 
terms of disease control and treatment related toxicities.  
   
 
 
 
 
 
 
 
 
